Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,050 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes.
Aggarwal N, Singla A, Mathieu C, Montanya E, Pfeiffer AFH, Johnsson E, Zhao J, Iqbal N, Bailey C. Aggarwal N, et al. Among authors: iqbal n. Diabetes Obes Metab. 2018 Feb;20(2):463-467. doi: 10.1111/dom.13104. Epub 2017 Oct 2. Diabetes Obes Metab. 2018. PMID: 28857388 Free PMC article. Clinical Trial.
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Del Prato S, Rosenstock J, Garcia-Sanchez R, Iqbal N, Hansen L, Johnsson E, Chen H, Mathieu C. Del Prato S, et al. Among authors: iqbal n. Diabetes Obes Metab. 2018 Jun;20(6):1542-1546. doi: 10.1111/dom.13258. Epub 2018 Mar 25. Diabetes Obes Metab. 2018. PMID: 29446523 Free PMC article. Clinical Trial.
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Handelsman Y, Mathieu C, Del Prato S, Johnsson E, Kurlyandskaya R, Iqbal N, Garcia-Sanchez R, Rosenstock J. Handelsman Y, et al. Among authors: iqbal n. Diabetes Obes Metab. 2019 Apr;21(4):883-892. doi: 10.1111/dom.13594. Epub 2019 Jan 3. Diabetes Obes Metab. 2019. PMID: 30499237 Free PMC article. Clinical Trial.
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Mathieu C, Rudofsky G, Phillip M, Araki E, Lind M, Arya N, Thorén F, Scheerer MF, Iqbal N, Dandona P. Mathieu C, et al. Among authors: iqbal n. Diabetes Obes Metab. 2020 Sep;22(9):1516-1526. doi: 10.1111/dom.14060. Epub 2020 May 22. Diabetes Obes Metab. 2020. PMID: 32311204 Free PMC article. Clinical Trial.
Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study.
Araki E, Mathieu C, Shiraiwa T, Maeda H, Ikeda H, Thoren F, Arya N, Asano M, Iqbal N. Araki E, et al. Among authors: iqbal n. Diabetes Obes Metab. 2021 Jul;23(7):1496-1504. doi: 10.1111/dom.14362. Epub 2021 Mar 15. Diabetes Obes Metab. 2021. PMID: 33620762 Free PMC article. Clinical Trial.
1,050 results